HYEI-YOON JUNG,HYUK-SANG KWON,JAE-HOON KANG,JONG-HEE KO,SEOK-WOO YANG,YEONG-MIN LEE,YONG-SUNG KIM
申请号：
BR112018004078
公开号：
BR112018004078A2
申请日:
2016.09.01
申请国别(地区):
BR
年份:
2018
代理人:
摘要：
the present invention relates to a pharmaceutical composition containing, an active ingredient, a fusion protein in which a tissue-penetrating peptide and an endothelial cell growth factor (anti-vegf) agent are fused, to treat cancer or angiogenesis-related diseases. more specifically, the present invention relates to the use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti-vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-vegf agent.the present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-vegf) agent are fused, for treating cancer or angiogenesis-related diseases. more specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti- vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-vegf agent.
